Alexion, Celgene, Biogen Fire on All Cylinders : The going has been good so far for the biotech sector in first-quarter earnings season. Most bigwigs surpassed on both earnings and sales. For instance, Biogen emerged with flying colors, fueled mainly by a strong performance of its newest drug, Spinraza. Other biotechs like Celgene and Incyte too beat on both counts. Also, Alexion's earnings and sales topped the Zacks Consensus Estimate in the first quarter and therefore, the company upped its guidance. Additionally, Vertex's earnings and sales exceeded expectations.